Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

y the European Medicines Agency (the "EMA") based on the pixantrone (PIX 301) phase III study results.  

For more information on the PIX-R trial, investigators and patients can visit www.pixrtrial.com, and www.clinicaltrials.gov.

About Pixantrone

Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert<
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  Medical Science Liaisons serve as a ... the healthcare sector. As the impact of technology in ... how Medical Science Liaisons (MSLs) interact with physicians and ... the tablet to not only share important disease and ... thought leader interactions across geographies and therapeutic areas. ...
(Date:8/22/2014)... 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... instrument for any modern science laboratory as ... materials. It can be broadly classified into ...
(Date:8/22/2014)... Research and Markets ( ... the  "Global Operating Room Equipment Market 2014-2018" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating room is ... a healthcare facility used to perform surgical ... equipment, which ensures patient care and enhanced ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... June 13 Telmisartan, an angiotensin receptor blocker, ... been studied in clinical trials in more than 50,000 patients. ... market exposure of 34.5 million patient years. Convincing safety data ... the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which ...
... Scientists from the Barbara Ann Karmanos Cancer Institute in ... agents used to promote bone health and inhibit resorption, may ... early stage breast cancer who take them for their anti-osteoporosis ... Society of Clinical Oncology Annual Meeting. , ...
Cached Medicine Technology:Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 2Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 3Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 4Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 5Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
(Date:8/22/2014)... Hudson County, NJ (PRWEB) August 22, 2014 ... that a leading specialist in Internal Medicine, Geriatrics, ... joined the network, CarePoint Health Medical Group. Their ... of highly skilled and experienced physicians comprise CarePoint ... doctors and practices in Hudson County, representing a ...
(Date:8/22/2014)... News) -- Back-to-school time provides an opportunity for parents ... family schedules, an expert suggests. "Forget New Year,s ... also be the start of a new fitness and ... kinesiology at the University of the Sciences in Philadelphia, ... extracurricular activities likely to build up, "it,s important for ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... of the National Commission on Macroeconomics and Health, K ... to make mandatory a comprehensive Universal Health Insurance System ... of 9 % of the GDP on health and ... growth and provision of basic infrastructural needs. ,Inaugurating ...
... The FDA has sent shock waves in the industry ... Nov. 8 from the U.S. Food and Drug Administration ... for qualified health claims for lycopene, tomatoes, and tomatoes-based ... lycopene (tomatoes, tomato-based foods containing lycopene) may reduce the ...
... Millennium Development Goals Memorandum signed between 189 countries from ... better health conditions to people in poor countries have ... these people had been reported in the Journal British ... make meaningful progress on the strategy aims - the ...
... various factors which are responsible for malaria infection and ... link to difference in genetic makeup between different individuals//. ... and colleagues were interested in the relative contributions of ... malaria. To estimate the overall contribution of genetic factors ...
... claimed 10 lives while over 3,000 people were suffering ... government officer said Friday//., ,"Nearly 3,000 tribal people ... have been in the grip of malaria and typhoid. ... three days," the district's acting collector Amir Ali said ...
... in the US have discovered a hormone that regulates ... the future//. ,Researchers at Stanford University, California, looked ... that codes for ghrelin, an appetite-boosting hormone. ... same protein precursor that produced ghrelin. The researchers say ...
Cached Medicine News:Health News:Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare 2Health News:Programs for development of health in poor countries not effective 2Health News:Researchers finding link between malaria susceptibility and genetic makeup 2
... Crossover system of implants and instruments provides ... posterior rod construct in the thoracic and ... system are available in three size ranges: ... can be used with the Isola, Pediatric ...
Portable ultrasound doppler system for peripheral and transcranial investigation....
Multiwindow transcranial and peripheral Doppler system....
Bi-Directional doppler volume flowmeter....
Medicine Products: